

Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis

Dong-Hua Liu^{1,2,#}, Yi-Le Ning^{1,3,#}, Yan-Yan Lei¹, Jing Chen^{1,2}, Yan-Yan Liu¹, Xin-Feng Lin¹, Zhong-Qi Yang^{3,4,*}, Shao-Xiang Xian^{3,4,*}, Wei-Tao Chen^{1,2,3,*}

1. Department of Critical Care Medicine, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
2. The First Clinical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
3. Ling-Nan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
4. The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.

Dong-Hua Liu and Yi-Le Ning contributed equally to this work. Both are considered the first authors of this article.

*Correspondence:

Zhong-Qi Yang: The First Affiliated Hospital, Guangzhou University of Chinese Medicine, No. 16, Jichang Road, Baiyun District, Guangzhou, Guangdong Province, 510405, China, Ling-Nan Medical Research Center, Guangzhou University of Chinese Medicine, No. 12, Jichang Road, Baiyun District, Guangzhou, Guangdong Province, 510405, China. E-mail: yang_zhongqi@163.com;

Shao-Xiang Xian: The First Affiliated Hospital, Guangzhou University of Chinese Medicine, No. 16, Jichang Road, Baiyun District, Guangzhou, Guangdong Province, 510405, China, Ling-Nan Medical Research Center, Guangzhou University of Chinese Medicine, No. 12, Jichang Road, Baiyun District, Guangzhou, Guangdong Province, 510405, China. E-mail: zhongyfy@126.com;

Wei-Tao Chen: Department of Critical Care Medicine, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, No. 16, Jichang Road, Baiyun District, Guangzhou, Guangdong Province, 510405, China. E-mail: chenweitao1900@gzucm.edu.cn.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Yes
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	Yes
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	Yes
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	Yes
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	Yes
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	Yes
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	Yes
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Yes
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	Yes
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	Yes
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Yes
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	Yes
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	Yes
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	Yes



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	Yes
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	No
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Yes
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Yes
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Yes
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Yes
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Yes
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Yes
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	No
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	Yes
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	Yes
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	Yes
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Yes

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.